Non-invasive low-level red-light therapy for axial length control in pediatric extreme myopia
Tian L, Cao K, Fan WY, Ohno-Matsui K, Ma DL, Duan AL, Jie Y
iScience · 3 citations
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- University or hospital
- Capital Health Research and Development of Special Fund
Based on 1 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2025-08-26 · iScience · vol. 28 · issue 10 · p. 113459
- Publisher
- Cell Press
- Cited
- 6 citations · more than 93% of similar papers · 3.4× the field average
- Impact
- Top 10% most cited in its field
- References
- 60 works
- Access
- Open access (journal) · CC-BY-NC-ND
- Research areas
- Corneal surgery and disorders · Ophthalmology and Visual Impairment Studies · Intraocular Surgery and Lenses
- Keywords
- Medicine
7 authors
From CN, JP
- Lei TianBeijing Tongren Hospital; Capital Medical University
- Kai CaoBeijing Tongren Hospital; Capital Medical University; Peking University
- Wen-Ying FanBeijing Tongren Hospital; Capital Medical University
- Kyoko Ohno-MatsuiInstitute of Science Tokyo
- Dong-Li MaBeijing Tongren Hospital; Capital Medical University
- An-Li DuanBeijing Tongren Hospital; Capital Medical University
Abstract
Extreme myopia presents a notable clinical challenge in management, with existing approaches having limitations. Repeated low-level red-light therapy (RLRL) has shown potential for myopia control. This multi-center prospective study included 59 children (101 eyes, aged 3-16.3 years) with extreme (SER ≤ -10D) or high myopia (-6D to -9.75D), who underwent twice-daily RLRL for 12 months 55 children (94 eyes) completed the follow-up. After treatment, significant improvements were observed: spherical equivalent error increased by 0.549D (95% confidence interval [CI]: 0.430 to 0.668, p p = 0.001), best-corrected visual acuity improved by 0.110 LogMAR, and choroidal thickness increased by 34.84 μm, with no adverse events. Subgroup analysis found comparable efficacy between the extreme and high myopia groups. These results indicate RLRL is a safe, non-invasive option for managing extreme myopia in children, with meaningful clinical value.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.